People · Operator
Named in public records as an officer, director or promoter · active 2012–2017 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| eGenesis, Inc. | — | Biotechnology | Series D+ | $265.0M | $316.4M | 2017 |
| Variation Biotechnologies (US), Inc. | — | Biotechnology | Series A | $17.1M | $54.2M | 2012 |
Stephen Gillis at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Stephen Gillis on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steven Gillis | 2 | 23 |
| Steve Gillis | 1 | 13 |
| SCOTT ROCKLAGE | 1 | 9 |
| PAUL SEKHRI | 1 | 7 |
| Bob More | 1 | 6 |
| Brad Smith | 1 | 6 |
| Lucio Iannone | 1 | 6 |
| Isaac Ciechanover | 1 | 5 |
| Geoff MacKay | 1 | 5 |
| Julie Sunderland | 1 | 5 |
| Jeffrey Leiden | 1 | 4 |
| Jeff Baxter | 1 | 4 |
| Michael Steinmetz | 1 | 4 |
| Sapna Srivastava | 1 | 3 |
| Rahul Kakkar | 1 | 3 |
| Egidio Nascimento | 1 | 3 |
| Kevin Forrest | 1 | 3 |
| Boris Nikolic | 1 | 3 |
| David E. Anderson | 1 | 3 |
| PETER HANSON | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.